thought call
inventori issu like overshadow otherwis good commerci
encourag posit pipelin progress
continu believ littl valu compani attract late-stag portfolio
reflect current inci share price much like attribut linger
neg sentiment olumi especi given fundament
busi remain strong third quarter patient growth jakafi core indic mf
y/i pv y/i robust despit neg inventori impact
us sale guidanc modestli increas compani effort
start pay next year like gvhd launch pdufa feb
launch effort way trial updat remain jakafi gvhd program
possibl line extens vitiligo phase data atop dermat
initi phase set serv addit catalystsal ahead larger potenti
indic essenti thrombocythemia addit potenti nda
pemigatinib cholangiocarcinoma capmatinib nsclc licens
novarti capabl provid addit revenu upsid ye along grow
list late-stag catalyst see continu see compel near-term upsid
stori although sentiment might improv rapidli compani
narrow focu late-stag pipelin licens earli
asset still would buyer current rang maintain ow pt
pipelin updat remain catalyst rich beyond jakafi gvhd program phase
data jak-inhibitor itacitinib treatment-nav gvhd expect
initi addit phase data baricitinib lilli atop
dermat anticip well updat citadel program
monotherapi r/r fl mzl mcl
model chang given updat commentari modestli lower
forecast vs vs reduc opex
estim non-gaap ep vs ep vs prior
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight compel mix
grow commerci asset interest pipelin
asset exclud epacadostat
epacadostat key pipelin driver compani
earlier pipelin program could result
share upsid also expect jakafi peak
royalti baricitinib repres
ww compel commerci perform
success earlier pipelin asset across portfolio
assum slower jakafi growth mf pf littl
uptak gvhd et similar minim
penetr olumi ra pipelin
assum failur pipelin agent itacitinib
pemigatinib
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
